---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-046920"
form_type: "8-K"
ticker: "OCGN"
cik: "0001372299"
company_name: "Ocugen, Inc."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T01:40:41.661585+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "medium"
source: SEC EDGAR
---

# Ocugen presents positive OCU400 clinical data: 84% less atrophy area in treated vs untreated

## Summary
- OCU400 (AAV encoding NR2E3) shows restoration of phototransduction genes and improved retinal structure in multiple RP/LCA models.
- Mean change in total atrophy area from baseline: +0.12 mm² treated vs +0.73 mm² untreated (84% improvement).
- LL VA change from baseline: treated patients improved while untreated declined over 12 months.
- Preclinical ERG and histology data show slowed degeneration across five animal models (Rho-/-, RhoP23H+/-, Rd7, Rd1, Rd16).

## SEC filing metadata
- accession: 0001628280-24-046920
- form_type: 8-K
- ticker: OCGN
- cik: 0001372299
- company_name: Ocugen, Inc.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: medium
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1372299/000162828024046920/0001628280-24-046920-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1372299/000162828024046920/ocgn-20241112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-046920
- JSON: https://secwatch.observer/filing/0001628280-24-046920.json
- Plain text: https://secwatch.observer/filing/0001628280-24-046920.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.